SCHEMBL6424796

SCHEMBL6424796

Clc1nc(C2CC2)ns1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14698860 0.89 NPC1 (0.41)
SCHEMBL12181006 0.79 FABP4 (0.30)
SCHEMBL31543251 0.79 GCK (0.34)
SCHEMBL23214263 0.75
SCHEMBL16024975 0.73
SCHEMBL1080305 0.73
SCHEMBL20711404 0.69 HCRTR1 (0.36)
SCHEMBL23964565 0.69 POLB (0.35)
SCHEMBL20202179 0.66 CHRNB2 (0.41)
SCHEMBL20320417 0.65 PDE10A (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545682-B2 Heterocyclic derivatives as P2X7 receptor antagonists BREYE THERAPEUTICS APS (DK) 2026-02-10 US disclosed
EP-4262975-B1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2025-03-05 EP disclosed
CN-111712492-B Cyclotriazoles as LPA antagonists 百时美施贵宝公司 2024-05-31 CN disclosed
US-20240034737-A1 Heterocyclic Derivatives as P2X7 Receptor Antagonists BREYE THERAPEUTICS APS (DK) 2024-02-01 US disclosed
CN-117157291-A Heterocyclic derivatives as P2X7 receptor antagonists 布雷耶疗法有限公司 2023-12-01 CN disclosed
EP-4262975-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Breye Therapeutics ApS (DK) 2023-10-25 EP disclosed
WO-2023084449-A1 DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2023-05-19 WO disclosed
EP-3728224-B1 CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-01-11 EP disclosed
WO-2022129365-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AXXAM S.P.A. (IT) 2022-06-23 WO disclosed
EP-4015039-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AXXAM S.p.A. (IT) 2022-06-22 EP disclosed
WO-2013189841-A1 NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2013-12-27 WO disclosed
WO-2013024168-A1 PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE REMYND NV (BE) 2013-02-21 WO disclosed
US-20100285957-A1 THIAZOLYLOXYPHENYLAMIDINES OR THIADIAZOLYLOXYPHENYLAMIDINES AND THEIR USE AS FUNGICIDES BAYER CROPSCIENCE AG (DE) 2010-11-11 US disclosed
WO-2005007636-A1 1,2,4- THIADIAZOL-5-THIO COMPOUNDS AND THE DERIVATIVES THEREOF, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS UREASE AND NITRIFICATION INHIBITORS SKW STICKSTOFFWERKE PIESTERITZ GMBH (DE) 2005-01-27 WO disclosed
CN-1143962-A Triazole compound and processes for preparation thereof YUHAN CORP (KR) 1997-02-26 CN disclosed
EP-0751943-A1 TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 1997-01-08 EP disclosed
WO-1995025107-A1 TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 1995-09-21 WO disclosed
US-5405853-A Potent muscarinic agonists having good central nervous system penetrability MERCK SHARPE & DOHME LTD. (GB) 1995-04-11 US disclosed
EP-0307142-B1 Thiadiazoles useful in the treatment of senile dementia MERCK SHARP & DOHME (GB) 1994-09-14 EP disclosed
EP-0307142-A1 Thiadiazoles useful in the treatment of senile dementia MERCK SHARP & DOHME LTD. (GB) 1989-03-15 EP disclosed